ICMJE DISCLOSURE FORM

Date:	5/10/2022
Your Name:	EDGARDO KAPLINSKY
Manuscript Title:	EMERGING CONCEPTS IN HEART FAILURE MANAGEMENT AND TREATEMENT: FOCUS ON VERICIGUAT
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		None	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).		None	
3	Royalties or licenses	X	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	X None FEES FOR CONSULTING UNRELATED TO	O THE PRSESENT WPRK
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None PAYMENTS / HONORARIA (LECTURES, PI PRESENT WORK	RESENTATIONS, ETC) UNRELATED TO THE
6	Payment for expert testimony	X None PAYMENTS FOR EXPERT TESTIMIN	OY UNRELATED TO THE PRESENT WORK
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or pending	X None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None UNRELATED WITH THE PRESENT WORK	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X None	
13	Other financial or non-financial interests	⊠ None	
Please place an "X" next to the following statement to indicate your agreement: X I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

ICMJE DISCLOSURE FORM

Date:	5/9/2022
Your Name:	SERGIO PERRONE
Manuscript Title:	EMERGING CONCEPTS IN HEART FAILURE MANAGEMENT AND TREATEMENT: FOCUS ON VERICIGUAT
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X	None	Click the tab key to add additional rows.
			Time frame: past 36 month	IS
2	Grants or contracts from any entity (if not indicated in item #1 above).		None	
3	Royalties or licenses	X	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	X None FEES FOR CONSULTING UNRELATED TO THE PRSESENT WPRK
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None PAYMENTS / HONORARIA (LECTURES, PRESENTATIONS, ETC) UNRELATED TO THE PRESENT WORK
6	Payment for expert testimony	None PAYMENTS FOR EXPERT TESTIMINOY UNRELATED TO THE PRESENT WORK
7	Support for attending meetings and/or travel	X None
8	Patents planned, issued or pending	X None
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None UNRELATED WITH THE PRESENT WORK
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None

			all entities with whom you have this nship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea X	Please place an "X" next to the following statement to indicate your agreement: X I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

ICMJE DISCLOSURE FORM

Date:	5/9/2022
Your Name:	ALEJANDRO BARBAGELATA
Manuscript Title:	EMERGING CONCEPTS IN HEART FAILURE MANAGEMENT AND TREATEMENT: FOCUS ON VERICIGUAT
Manuscript Number (if known):	Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initial planning	of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X	None	Click the tab key to add additional rows.
			Time frame: past 36 month	IS
2	Grants or contracts from any entity (if not indicated in item #1 above).		None	
3	Royalties or licenses	X	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	X None FEES FOR CONSULTING UNRELATED TO THE PRSESENT WPRK
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X None PAYMENTS / HONORARIA (LECTURES, PRESENTATIONS, ETC) UNRELATED TO THE PRESENT WORK
6	Payment for expert testimony	None PAYMENTS FOR EXPERT TESTIMINOY UNRELATED TO THE PRESENT WORK
7	Support for attending meetings and/or travel	X None
8	Patents planned, issued or pending	X None
9	Participation on a Data Safety Monitoring Board or Advisory Board	X None UNRELATED WITH THE PRESENT WORK
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X None

			all entities with whom you have this nship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea X	Please place an "X" next to the following statement to indicate your agreement: X I certify that I have answered every question and have not altered the wording of any of the questions on this form.			